Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (trading symbol: CYCC) on June 3, 2025. The registrant is incorporated in Delaware and maintains its principal executive offices in Kuala Lumpur, Malaysia. The filing addresses a specific regulatory event regarding the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a corporate event and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Regulatory Compliance: The company previously received notice from Nasdaq on December 12, 2024, regarding non-compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)), which mandates a minimum bid price of $1.00 per share for 30 consecutive business days.
- Resolution: On June 3, 2025, the company received a compliance letter from Nasdaq confirming it has regained compliance with the listing rule. The compliance matter is now closed.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding potential future transactions and stockholder approvals. Management directs investors to the "Risk Factors" section of the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 10-Q for the quarter ended March 31, 2025, for a comprehensive list of risks and uncertainties. No specific financial guidance or outlook is provided in this document.
Investor Verification Checklist
- Verify the current trading price of CYCC to ensure continued compliance with Nasdaq listing rules post-remediation.
- Review the attached Press Release (Exhibit 99.1) for any additional details on the compliance process.
- Consult the most recent Form 10-K and Form 10-Q for actual financial performance data, as this 8-K contains no financial metrics.
- Monitor future filings for any new Nasdaq deficiency notices or changes in listing status.